Wegovy (semaglutide) Injector is a prescription medication used to treat obesity in adults who have a body mass index (BMI) of 30 kg/m or greater, or in adults with a BMI of 27 kg/m or greater who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Already known to increase GLP-1 secretion, ingestion of Lactobacillus reuteri demonstrates increased GLP-2 secretion as well (Simon et al., 2015)
The maximum tolerated dose of tirzepatide appears to be effective
Last medically reviewed: 2026-06-08 by GLP3 Planner editorial
Martinez, D., Lee, H., & Patel, S
Lancet Diabetes Endocrinol, 10 , 193206